Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Pharma
As AZ hits $45B revenue goal, is Enhertu nearing a plateau?
Enhertu's new patient share in HER2-low breast cancer appears to have flattened, raising questions about the indication's real market opportunity.
Angus Liu
Feb 8, 2024 10:48am
Daiichi keeps dialing up Enhertu forecast, advances 2nd AZ ADC
Jan 31, 2024 3:42pm
JPM24: Pfizer oncology head still eyes ADC deals under new org
Jan 11, 2024 11:03am
NICE poised to reject Enhertu in HER2-low breast cancer
Sep 27, 2023 10:51am
Seagen's breast cancer drug Tukysa boosts Roche's ADC
Aug 17, 2023 10:18am
ASCO: Enhertu delivers 'very compelling' pan-tumor activity
Jun 5, 2023 8:00am